NAD+ 1000mg
In Stock & Ready to Ship from USA
FREE shipping on every U.S. order
Secure checkout via encrypted payment processor
+2.9kResearch Use Only
These products are for laboratory research only and not intended for medical use. They are not FDA-approved to diagnose, treat, cure, or prevent any disease. By purchasing, you certify they will be used solely for research and not for human or animal consumption.
Research Summary
26 PubMed CitationsOverview NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every living cell, serving a dual function as an electron transporter in redox reactions (glycolysis, TCA cycle → ATP production) and a critical substrate for non-redox signaling enzymes including sirtuins (SIRT1–7), PARPs, CD38/CD157, and SARM1.[1][2] Mammalian cells synthesize NAD+ through three primary pathways: De Novo Synthesis: From L-tryptophan via the kynurenine pathway Preiss-Handler Pathway: From nicotinic acid (vitamin B3) Salvage Pathway (dominant): Recycling nicotinamide (NAM) via NAMPT → NMN → NAD+ (rate-limiting enzyme: NAMPT) NAD+ levels in human tissues decline 10–65% with age, driven by reduced NAMPT activity and increased consumption by CD38/PARPs during chronic inflammation. This decline is now considered a hallmark of aging.[1][3] NAD+ was originally discovered in 1906 by Arthur Harden and William John Young during fermentation studies, with its structure elucidated by Hans von Euler-Chelpin (1929) and its hydride transfer function identified by Otto Heinrich Warburg...
NAD+ — Research Data at a Glance
| Property | Value |
|---|---|
| PubMed Citations Referenced | 26 |
| Contributing Researchers | 3 |
| Storage Conditions | Store NMN/NAD+ powder at −20°C; protect from light and moisture. |
| Purity Standard | Not reported on the published certificate |
| Research Use Only | Not for human consumption. RUO only. |
Compare NAD+ with Other Peptides
Research guide
What is NAD+? Read the full research guideOverview
Overview
NAD+ (Nicotinamide Adenine Dinucleotide) is a coenzyme present in every living cell, serving a dual function as an electron transporter in redox reactions (glycolysis, TCA cycle → ATP production) and a critical substrate for non-redox signaling enzymes including sirtuins (SIRT1–7), PARPs, CD38/CD157, and SARM1.[1][2]
Mammalian cells synthesize NAD+ through three primary pathways:
- De Novo Synthesis: From L-tryptophan via the kynurenine pathway
- Preiss-Handler Pathway: From nicotinic acid (vitamin B3)
- Salvage Pathway (dominant): Recycling nicotinamide (NAM) via NAMPT → NMN → NAD+ (rate-limiting enzyme: NAMPT)
NAD+ levels in human tissues decline 10–65% with age, driven by reduced NAMPT activity and increased consumption by CD38/PARPs during chronic inflammation. This decline is now considered a hallmark of aging.[1][3]
NAD+ was originally discovered in 1906 by Arthur Harden and William John Young during fermentation studies, with its structure elucidated by Hans von Euler-Chelpin (1929) and its hydride transfer function identified by Otto Heinrich Warburg (1936).[2]
Modern resurgence: Discovery that sirtuin enzymes consume NAD+ as an obligate cofactor (Imai 2000) reframed NAD+ from a passive redox carrier to an active signaling-network hub. The "NAD World" framework articulated by Imai positions NAMPT as the rate-limiting salvage enzyme and NMN as a critical extracellular signaling intermediate maintaining systemic biological robustness. Sinclair and colleagues subsequently demonstrated that pharmacologic NAD+ replenishment in aged mice rescues mitochondrial-nuclear communication, restores capillary density and exercise endurance (Das 2018), and mimics caloric-restriction phenotypes — establishing NAD+ decline as a tractable hallmark-of-aging target rather than an immutable consequence of senescence.[3][14]
Research framework: The contemporary NAD+ literature distinguishes three precursor strategies — direct NAD+ (with limited intracellular bioavailability per Grant 2019), NMN supplementation (bioavailable via Slc12a8 transporter, validated by Yoshino 2021 prediabetic-women trial), and NR (bioavailable via ENT transporters, GRAS status, validated by Trammell 2016 dose-response and Brakedal 2022 NADPARK Parkinson's trial). Christen 2025 (Nature Metabolism) provided head-to-head comparison: NMN and NR each elevated circulating NAD+ ~2-fold over 14 days, while equivalent-dose nicotinamide (NAM) did not — highlighting that gut microbiota convert NMN/NR through nicotinic acid intermediates rather than direct cellular uptake. Researchers studying related metabolic and longevity compounds commonly cross-reference our MOTS-c, Glutathione, and Epithalon pages for parallel mitochondrial, antioxidant, and geroprotector pharmacology.[4]
Mechanism of Action
Mechanism of Action
1. Sirtuin Activation (SIRT1–7)
Sirtuins are NAD+-dependent protein deacylases (class III histone deacetylases). They bind NAD+ and an acetylated target protein, cleaving the glycosidic bond to release nicotinamide (NAM) and generate O-acetyl-ADP-ribose. Km range: 94–888 µM.[6]
- SIRT1 Pathway: Deacetylates PGC-1α → mitochondrial biogenesis; FOXO → stress resistance; also deacetylates LKB1 → activates AMPK → positive feedback loop increasing NAD+ and fatty acid oxidation[6]
- SIRT3 Pathway: Mitochondrial localization; deacetylates MnSOD → enhanced antioxidant defense; activates OXPHOS enzymes[6]
2. PARP1/2 DNA Repair
PARP1 detects DNA strand breaks → consumes NAD+ to build poly(ADP-ribose) chains → recruits repair enzymes (XRCC1). Km 20–97 µM — higher affinity than sirtuins, can outcompete for NAD+ during DNA damage. Excessive activation → NAD+/ATP depletion → parthanatos (cell death).[6][1]
3. CD38/CD157 Hydrolysis
CD38 is the major regulator of tissue NAD+ levels (Km ~15–25 µM). It hydrolyzes NAD+ into NAM and ADP-ribose, and cyclizes NAD+ into cADPR → Ca²⁺ mobilization from intracellular stores. CD38 expression increases with aging, directly driving NAD+ decline.[1][8]
4. SARM1 Axonal NADase
SARM1 contains a TIR domain with intrinsic NADase activity. Activated by nerve injury → rapid axonal NAD+ depletion → local metabolic collapse and calcium influx → Wallerian degeneration.[7]
5. Extracellular Signaling
Extracellular NAD+ acts at P2X7 purinergic receptors on T-regulatory cells → ART2-P2X7 pathway → immune modulation.[6]
Precursor Entry Mechanisms
| Precursor | Cellular Entry | Notes |
|---|---|---|
| NAD+ (direct) | Cannot passively cross plasma membrane | Exception: Connexin 43 in heart muscle |
| NR | Equilibrative nucleoside transporters (ENTs) | Best oral bioavailability; GRAS status |
| NMN | Dephosphorylated → NR by CD73 extracellularly | Slc12a8 transporter in small intestine |
| NAM | Passive diffusion | Feedback-inhibits sirtuins/PARPs at high concentrations |
Substrate Competition & Tissue NAD+ Dynamics
The relative Km values of the three NAD+-consuming enzyme classes (PARP1 20-97 µM, sirtuins 94-888 µM, CD38 ~15-25 µM) determine which pathway dominates under given cellular conditions. CD38's low Km positions it as the major regulator of tissue NAD+ levels under baseline conditions, while PARP1 outcompetes sirtuins during acute DNA-damage events. Excessive PARP1 activation can deplete NAD+ to the point of ATP collapse and parthanatos cell death. CD38 expression rises with aging — driving the 10-65% NAD+ decline observed in aged human brain, liver, and skin tissues. Tarragó 2018 demonstrated that CD38 inhibition (78c compound) in 32-month-old mice restored tissue NAD+ across liver, muscle, and heart, reversing age-associated metabolic dysfunction — establishing CD38 inhibition as a parallel pharmacologic strategy to NAD+ precursor supplementation.[1][8]
Microbiome-Mediated Bioavailability
Christen 2025 head-to-head trial (n=65) demonstrated that NMN and NR are extensively metabolized by gut microbiota into nicotinic acid (NA) intermediates before systemic uptake — explaining why intracellular NAD+ rises despite limited direct intestinal absorption of intact NMN/NR. This finding reframes earlier debate over NMN-versus-NR bioavailability as largely a question of microbiome composition rather than transporter expression, and helps explain inter-subject variability observed across earlier trials. Equivalent-dose nicotinamide (NAM) failed to elevate NAD+, consistent with NAM's role as a sirtuin-feedback inhibitor at high concentrations.[4]
Research Applications
Research Applications
NAD+ research spans aging biology, metabolic disease, neurodegeneration, and cardiovascular health with 15+ clinical trials and extensive preclinical data:
- Aging and Longevity — Declining NAD+ is a hallmark of aging; supplementation mimics caloric restriction, rejuvenates stem cells, extends healthspan in mice.[3][9]
- Metabolic Disorders — NMN was studied for muscle insulin-sensitivity endpoints in prediabetic women (Yoshino 2021, Science). NR prevented diet-induced obesity 40% in mice.[10][11]
- Neurodegenerative Diseases — Alzheimer's (NMN → restored spatial memory), Parkinson's (NADPARK: NR → increased cerebral NAD+, MRS-confirmed), ALS (NR + pterostilbene → improved function).[12][13]
- Cardiovascular Health — Heart failure, cardiomyopathy, ischemia-reperfusion; NMN restores capillary density/endurance 80% in aged mice (SIRT1-dependent vascular rejuvenation).[14]
- DNA Repair / Cancer — NAD+ is sole PARP substrate; complex dual role in genomic stability vs tumor metabolism.[1]
- Immune Modulation — CD38 on macrophages drives M1/M2 polarization; CD38 inhibitors (78c, apigenin) reverse age-related NAD+ decline.[8]
- Acute Organ Injury — NMN protects against cisplatin-induced AKI (SIRT1-dependent); NAD+ reduced brain infarct volume in rodent ischemia models.[15]
- Ophthalmology — Photoreceptor survival, retinal degeneration, glaucoma.[2]
- Fertility — NMN restores oocyte quality, improves ovulation, rescues fertility in aged female mice.[2]
- CD38 Pathway Pharmacology — Tarragó 2018 (78c CD38 inhibitor in aged mice) and apigenin/luteolin natural CD38 inhibitors used as research tools to dissect CD38-mediated NAD+ decline separate from precursor supplementation.[8]
- Microbiome-Pharmacokinetic Studies — Christen 2025 head-to-head NMN vs NR vs NAM (n=65) established gut-bacterial NA intermediates as the dominant route of intracellular NAD+ replenishment, reframing precursor-bioavailability research toward microbiome composition.[4]
Comparative Research Context
NAD+ research occupies the intersection of three adjacent fields: mitochondrial biology and bioenergetics, aging and longevity pharmacology, and signaling-enzyme cofactor biochemistry. The signature pharmacology — sirtuin / PARP / CD38 / SARM1 substrate competition with widely different Km values — distinguishes NAD+ from receptor-targeted aging interventions and supports its use as a tool molecule for dissecting how cells partition a finite cofactor pool across competing enzymatic demands. Researchers comparing NAD+ precursor pharmacology with related mitochondrial and longevity peptides commonly cross-reference our MOTS-c, Glutathione, SS-31, and Epithalon pages for parallel mitochondrial-protective, antioxidant, and geroprotector pharmacology. The Mills 2016 long-term mouse study, Yoshino 2021 prediabetic-women trial, Brakedal 2022 NADPARK Parkinson's trial, and Christen 2025 head-to-head precursor study together establish NAD+ pharmacology as one of the best-characterized longevity intervention programs in current research.
Biochemical Characteristics
| Property | Value |
|---|---|
| Molecular Formula | C₂₁H₂₇N₇O₁₄P₂ |
| Molecular Weight | 663.43 g/mol |
| CAS Number | 53-84-9 |
| PubChem CID | 5893 |
| Structure | Dinucleotide: adenosine 5′-phosphate + ribosylnicotinamide 5′-phosphate joined by pyrophosphate linkage |
| Classification | Coenzyme (NOT a peptide/protein) |
| Redox States | NAD+ (oxidized) ↔ NADH (reduced, accepts hydride ion) |
| Synonyms | Coenzyme I, diphosphopyridine nucleotide, oxidized nicotinamide adenine dinucleotide |
| Key Precursors | NMN (CID: 14180), NR (Niagen®), NAM, NA, L-Tryptophan |
| Rate-Limiting Enzyme | NAMPT (nicotinamide phosphoribosyltransferase) — Salvage pathway |
| Plasma Half-Life | ~1–2h cytoplasm/nucleus; ~8h mitochondria |
Identifiers
| Identity Confirmation | |
|---|---|
| Endotoxin | |
| Quality Control |
Preclinical Research Summary
Preclinical Research Summary
Key Preclinical Studies
| Study | Model | Key Findings | Ref |
|---|---|---|---|
| Mills et al. (2016) | C57BL/6N mice — NMN 100–300 mg/kg/day × 12 mo | Suppressed weight gain ~10% (p<0.001); increased energy expenditure; improved insulin sensitivity; no obvious toxicity | [17] |
| Das et al. (2018) | Elderly C57BL/6 mice — NMN 500 mg/kg/day × 28d | Capillary density restored to young-mouse levels; endurance improved 80% via SIRT1-dependent vascular rejuvenation | [14] |
| Hou et al. (2018) | 3xTgAD Alzheimer's mice — NMN 100 mg/kg × 28d–3mo | Decreased Aβ oligomers; restored spatial memory in water maze tasks | [2] |
| Zhang et al. (2016) | Aged C57BL/6 mice — NR 400 mg/kg/day × ~6mo | Extended median lifespan 5% (p<0.05); enhanced muscle stem cell function; increased grip strength | [9] |
| Cantó et al. (2012) | HFD mice — NR 400 mg/kg/day × 8–12 wk | Prevented weight gain (40% less than controls); increased thermogenesis | [11] |
| Ying/Won (2007/2012) | Rat ischemia — NAD+ 10–20 mg/kg × 2h post-injury | Reduced infarct volume (p<0.01); bypasses BBB; profound neuroprotection | [15] |
| Tarragó et al. (2018) | Aged mice (32 mo) — 78c (CD38 inhibitor) | Increased NAD+ in liver/muscle/heart; improved glucose tolerance | [8] |
Human Clinical Data: NMN Trials
| Trial | Population | Design | Key Results | Ref |
|---|---|---|---|---|
| Christen et al. (2025) | n=65 healthy adults | NMN vs NR vs NAM × 14d | NAD+ and gut-microbial NA-intermediate endpoints | [4] |
| Yoshino et al. (2021) | n=25 prediabetic women | NMN × 10 wk | Muscle insulin-sensitivity endpoints | [10] |
| Pencina et al. (2023) | n=32 overweight 55–80y | MIB-626 × 14–28d | NAD+ metabolite, body-weight and blood-pressure endpoints reported | [20] |
Human Clinical Data: NR Trials
| Trial | Population | Design | Key Results | Ref |
|---|---|---|---|---|
| Trammell et al. (2016) | n=12 healthy adults | NR, single administration, escalating levels | NAD+ metabolome endpoints | [5] |
| Martens et al. (2018) | n=24 ages 55–79 | NR × 6 wk | PBMC NAD+, blood-pressure and aortic-stiffness endpoints | [21] |
| Brakedal et al. (2022) — NADPARK | n=30 Parkinson's | NR × 30d | Cerebral NAD+ and motor endpoints | [12] |
| Wang et al. (2022) | n=30 HFrEF | NR × 12 wk | Blood NAD+, NLRP3 and cardiac-function endpoints | [22] |
| Wu et al. (2025) | Older adults with MCI | NR × 8 wk | Plasma pTau217 endpoint | [13] |
| de la Rubia et al. (2019) | n=32 ALS | NR + pterostilbene × 16 wk | ALSFRS, pulmonary-function and strength endpoints | [23] |
Direct NAD+ Data
| Trial | Population | Design | Key Results | Ref |
|---|---|---|---|---|
| Grant et al. (2019) | n=11 healthy men | NAD+, 6 h exposure | Plasma and PBMC NAD+ endpoints | [24] |
Safety Summary
| Parameter | Finding |
|---|---|
| NR Safety | Studied up to 12 weeks — GRAS status; no serious AEs |
| NMN Safety | No serious AEs reported in 4-week and 12-week studies |
| Theoretical Risks | Tumorigenesis (not observed in long-term animal studies); SARM1 axonal degeneration; methylation depletion from excess NAM |
The products offered on this website are furnished for in-vitro studies only. In-vitro studies (Latin: in glass) are performed outside of the body. These products are not medicines or drugs and have not been approved by the FDA to prevent, treat or cure any medical condition, ailment or disease. Bodily introduction of any kind into humans or animals is strictly forbidden by law.
For Laboratory Research Only. Not for human use, medical use, diagnostic use, or veterinary use.
ALL ARTICLES AND PRODUCT INFORMATION PROVIDED ON THIS WEBSITE ARE FOR INFORMATIONAL AND EDUCATIONAL PURPOSES ONLY.
Authors & Attribution
✍️ Article Author
Prof. David A. Sinclair
David A. Sinclair, PhD, is Professor of Genetics at Harvard Medical School and Co-Director of the Paul F. Glenn Center for the Biological Mechanisms of Aging. Prof. Sinclair's laboratory established that NAD+ levels decline with age and that this decline compromises the activity of sirtuins (SIRT1), enzymes critical for DNA repair and longevity. His work has focused on developing 'NAD-boosting' molecules (NMN) to restore metabolic function and extend healthspan. He authored seminal reviews: 'Slowing ageing by design: the rise of NAD+ and sirtuin-activating compounds' (2016) and 'Therapeutic potential of NAD-boosting molecules' (2018). David A. Sinclair is being referenced as one of the leading scientists involved in NAD+ research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
View Full Researcher Profile →🎓 Scientific Journal Author
Dr. Shin-ichiro Imai
Shin-ichiro Imai, MD, PhD, is at Washington University School of Medicine. Dr. Imai formulated the 'NAD World' conceptual framework (now NAD World 3.0), positioning NAD+ metabolism as a systemic regulatory network connecting metabolism, biological rhythm, and aging. He has extensively studied NAMPT as the rate-limiting salvage enzyme and positioned NMN as a critical signaling molecule for maintaining biological robustness. Key publications include the NMN diabetes mouse study (2011, Cell Metabolism), 'NAD+ and sirtuins in aging and disease' (2014), and 'NAD World 3.0' (2025). Shin-ichiro Imai is being referenced as one of the leading scientists involved in NAD+ research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
View Full Researcher Profile →Dr. Shin-ichiro Imai is being referenced as one of the leading scientists involved in the research and development of NAD+. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.
🔬 Contributing Researcher
Dr. Charles Brenner
Charles Brenner, PhD, holds the Alfred E. Mann Family Foundation Chair in Diabetes and Cancer Metabolism at City of Hope National Medical Center and serves as Chief Scientific Advisor at Niagen Bioscience. In 2004, Dr. Brenner discovered the nicotinamide riboside kinase (NRK) pathway, establishing NR as a vitamin precursor to NAD+. He led the first clinical trial establishing NR safety and bioavailability in humans (2016, Nature Communications). His foundational work includes 'Discoveries of nicotinamide riboside as a nutrient and conserved NRK genes' (2004) and 'Nicotinic acid, nicotinamide, and nicotinamide riboside: a molecular evaluation of NAD+ precursor vitamins in human nutrition' (2008). Charles Brenner is being referenced as one of the leading scientists involved in NAD+ research. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor.
View Full Researcher Profile →Dr. Charles Brenner is being referenced as one of the leading scientists involved in the research and development of NAD+. In no way is this doctor/scientist endorsing or advocating the purchase, sale, or use of this product for any reason. There is no affiliation or relationship, implied or otherwise, between Pure US Peptide and this doctor. The purpose of citing the doctor is to acknowledge, recognize, and credit the exhaustive research and development efforts conducted by the scientists studying this peptide.
Referenced Citations
Covarrubias AJ, Perrone R, Grozio A, Verdin E. NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. 2021;22(2):119-141.
DOIRajman L, Chwalek K, Sinclair DA. Cell Metabolism. 2018;27(3):529-547.
DOIVerdin E. NAD+ in aging, metabolism, and neurodegeneration. Science. 2015;350(6265):1208-1213.
DOIChristen S, Redeuil K, Goulet L, et al. Nature Metabolism. 2025 Jan 15 [Epub].
DOITrammell SAJ, Schmidt MS, Weidemann BJ, et al. Nature Communications. 2016;7(1):12948.
DOIImai S, Guarente L. NAD+ and sirtuins in aging and disease. Trends in Cell Biology. 2014;24(8):464-471.
DOIEssuman K, Summers DW, Sasaki Y, Mao X, DiAntonio A, Milbrandt J. The SARM1 Toll/interleukin-1 receptor domain possesses intrinsic NAD+ cleavage activity that promotes pathological axonal degeneration. Neuron. 2017;93(6):1334-1343.e5.
DOITarragó MG, Chini CCS, Kanamori KS, et al. Cell Metabolism. 2018;27(5):1081-1095.e10.
DOIZhang H, Ryu D, Wu Y, et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science. 2016;352(6292):1436-1443.
DOIYoshino M, Yoshino J, Kayser BD, et al. Science. 2021;372(6547):1224-1229.
DOICantó C, Houtkooper RH, Pirinen E, et al. Cell Metabolism. 2012;15(6):838-847.
DOIBrakedal B, Dölle C, Riber F, et al. Cell Metabolism. 2022;34(3):396-407.e6.
DOIWu J, et al. Alzheimer's & Dementia: TRCI. 2025.
PubMedDas A, Huang GX, Bonkowski MS, et al. Impairment of an endothelial NAD+-H₂S signaling network is a reversible cause of vascular aging. Cell. 2018;173(1):74-89.e20.
DOIGuan Y, Wang SR, Huang XZ, et al. Nicotinamide mononucleotide, an NAD+ precursor, rescues age-associated susceptibility to AKI in a sirtuin 1-dependent manner. Journal of the American Society of Nephrology. 2017;28(8):2337-2352.
DOILiao B, Zhao Y, Wang D, Zhang X, Hao X, Hu M. Journal of the International Society of Sports Nutrition. 2021;18(1):54.
DOIMills KF, Yoshida S, Stein LR, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism. 2016;24(6):795-806.
DOIIgarashi M, Nakagawa-Nagahama Y, Miura M, et al. npj Aging. 2022;8(1):5.
DOIYi L, Maier AB, Tao R, et al. GeroScience. 2023;45(1):29-43.
DOIPencina KM, Lavu S, Dos Santos M, et al. Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2023;78(1):90-96.
DOIMartens CR, Denman BA, Mazzo MR, et al. Nature Communications. 2018;9(1):1286.
DOIWang DD, et al. JACC: Basic to Translational Science. 2022.
PubMedde la Rubia JE, Drehmer E, Platero JL, et al. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 2019;20(1-2):115-122.
DOIGrant R, Berg J, Mestayer R, et al. Frontiers in Aging Neuroscience. 2019;11:257.
DOIYoshino J, Mills KF, Yoon MJ, Imai S. Cell Metabolism. 2011;14(4):528-536.
DOIPoljsak B, Kovač V, Špalj S, Milisav I. International Journal of Molecular Sciences. 2023;24(3):2959.
DOIRUO Disclaimer
For Research Use Only (RUO). Not intended for human consumption, clinical use, or as a drug, food, cosmetic, or medical device. This product has not been evaluated by the FDA and is supplied solely for in-vitro laboratory research by qualified professionals.
Certificate of Analysis
Published certificates come from third-party laboratories. If this listing's certificate is still pending, the card below says so.
Latest Lab Report
Storage & Handling
Summary
Store NMN/NAD+ powder at −20°C; protect from light and moisture.
Recommended Laboratory Storage Conditions
Lyophilized Powder: Store at −20°C for long-term stability. White to slightly yellow crystalline powder. Protect from light and moisture in dark, airtight containers.
Salt Forms: NR often stabilized as Nicotinamide Riboside Chloride (Niagen®).
Handling: Standard laboratory safety precautions (gloves, goggles). No CYP450 metabolism for direct NAD+.
“Preclinical Research Summary Key Preclinical Studies Study Model Key Findings Ref Mills et al.”
Related Research Compounds
5-Amino 1MQ
50mg
MOTS-C
40mg
Glutathione
1500mg